MODY (Maturity-Onset Diabetes of the Young)

📋 Key Information Summary

📋

MODY (Maturity-Onset Diabetes of the Young) is a monogenic form of diabetes caused by single-gene mutations affecting pancreatic beta-cell function; it accounts for 1–5 % of all paediatric and young-adult diabetes.
MODY is often misdiagnosed as type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM); correct diagnosis changes management in the majority of cases.
At least 14 subtypes are recognised; MODY 1–6 are the best characterised (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1).
MODY 2 (GCK mutations) causes mild, stable fasting hyperglycaemia (5.5–8.0 mmol/L) and usually requires no pharmacological treatment.
MODY 3 (HNF1A mutations) is the most common subtype in Australia; patients are exquisitely sensitive to low-dose sulphonylureas and this is the preferred therapy.
MODY 1 (HNF4A) responds similarly to sulphonylureas; MODY 5 (HNF1B) is associated with renal cysts and often requires insulin.
Genetic testing (targeted gene panel or whole-exome sequencing) is the gold standard for diagnosis; available through Australian public genetics services.
MODY follows autosomal dominant inheritance — each child of an affected parent has a 50 % chance of inheriting the mutation.
Key diagnostic clues: non-obese, young onset (<25 years), family history of diabetes in ≥2 generations, absence of pancreatic autoantibodies, detectable C-peptide.
Correct diagnosis of MODY 3 allows transition from insulin to low-dose sulphonylurea, improving glycaemic control and quality of life.
HbA1c targets: 6.5 % (48 mmol/mol) or individualised; MODY 2 patients typically have HbA1c < 7.0 % without treatment.
Cascade genetic testing of first-degree relatives is recommended to identify undiagnosed family members.

🎧 Audio Brief

Replacing Daily Insulin Shots with a Pill

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

MODY (Maturity-Onset Diabetes of the Young) is a monogenic form of diabetes mellitus caused by single-gene mutations that impair pancreatic beta-cell development, insulin secretion, or both. Unlike type 1 diabetes mellitus (T1DM), MODY is not autoimmune; unlike type 2 diabetes mellitus (T2DM), it is not primarily driven by insulin resistance. MODY typically presents in adolescents or young adults who are often non-obese and have a strong family history of diabetes spanning multiple generations in an autosomal dominant pattern.

MODY accounts for approximately 1–5 % of all cases of diabetes diagnosed before the age of 25 years. In Australia, MODY is likely underdiagnosed due to its clinical overlap with T1DM and T2DM. A 2018 study from the Royal Melbourne Hospital genetics service estimated that fewer than 10 % of eligible patients are referred for genetic testing. Prevalence estimates from European and North American registries suggest roughly 68–100 cases per million population; Australian data are limited but the condition is recognised at major tertiary centres and through the Australian Genomics Health Alliance.

Accurate diagnosis of MODY is clinically important because it determines prognosis, guides therapy (particularly the use of sulphonylureas in MODY 3), informs family screening, and may allow cessation of unnecessary insulin therapy. The three most common subtypes — MODY 3 (HNF1A), MODY 2 (GCK), and MODY 1 (HNF4A) — together account for over 80 % of genetically confirmed cases worldwide.

Genetics & Types (MODY 1–6)

MODY follows autosomal dominant inheritance with high penetrance. Each child of an affected parent carries a 50 % risk of inheriting the pathogenic variant. The condition is caused by heterozygous loss-of-function mutations in genes critical for beta-cell development, glucose sensing, or insulin transcription and secretion. At least 14 subtypes are now recognised; the first six are the best characterised and most clinically relevant.

Subtype	Gene	Prevalence	Mechanism	Key Features
MODY 1	HNF4A	~5 %	Impaired insulin transcription & secretion	Progressive hyperglycaemia; neonatal macrosomia and transient neonatal hypoglycaemia; responds to sulphonylureas
MODY 2	GCK	~30–50 %	Defective glucose sensing (glucokinase)	Mild stable fasting hyperglycaemia (5.5–8.0 mmol/L); HbA1c typically 5.8–7.6 %; usually no treatment required
MODY 3	HNF1A	~30–50 %	Reduced beta-cell transcription factor function	Most common subtype; progressive hyperglycaemia; renal glycosuria (low renal threshold); exquisitely sensitive to sulphonylureas
MODY 4	PDX1 (IPF1)	<1 %	Impaired pancreas development & insulin gene expression	Rare; may cause pancreatic agenesis in homozygotes; heterozygotes develop late-onset diabetes
MODY 5	HNF1B	~5–7 %	Renal cysts and diabetes syndrome (RCAD)	Renal cystic disease, renal malformations, pancreatic hypoplasia; often requires insulin; renal function monitoring essential
MODY 6	NEUROD1	<1 %	Impaired insulin gene transcription & neuronal development	Very rare; may have neurological features; responds to sulphonylureas or insulin

ℹ️

Genetic testing availability in Australia: Targeted MODY gene panels are available through public genetics services at Royal Melbourne Hospital, Royal Adelaide Hospital, and Sydney Children's Hospital. Whole-exome sequencing (WES) is accessible via Medicare-funded genomic testing for qualifying patients. Referral to a clinical geneticist or endocrinologist with monogenic diabetes expertise is recommended.

Clinical Features & Diagnosis

When to Suspect MODY

MODY should be considered in any patient with diabetes who does not clearly fit the typical T1DM or T2DM profile. The following clinical features raise the probability of MODY:

Diagnosis before age 25 years (though MODY 1 and 3 may present later)
Non-obese (BMI < 25 kg/m²) with no features of metabolic syndrome
Family history of diabetes in ≥ 2 consecutive generations (autosomal dominant pattern)
Negative pancreatic autoantibodies (GAD65, IA-2, ZnT8)
Preserved C-peptide secretion (fasting C-peptide > 200 pmol/L, or stimulated > 600 pmol/L)
No history of diabetic ketoacidosis (DKA)
Mild, stable hyperglycaemia without significant glycaemic variability (particularly MODY 2)
Renal glycosuria with normal blood glucose (suggestive of MODY 3/HNF1A)
Neonatal macrosomia followed by childhood-onset diabetes (suggestive of MODY 1/HNF4A)
Renal cysts or urogenital malformations with diabetes (suggestive of MODY 5/HNF1B)

Diagnostic Pathway

The diagnostic workup for suspected MODY follows a stepwise approach:

1

Clinical Suspicion

Identify patients who do not fit typical T1DM or T2DM criteria using the Royal Devon & Exeter MODY probability calculator or clinical judgement.

2

Exclude Autoimmune & Insulin-Resistant Diabetes

Check GAD65 and IA-2 autoantibodies; measure fasting C-peptide; assess BMI and features of insulin resistance.

3

Genetic Testing

Refer to a genetics service for targeted MODY gene panel sequencing (or WES if panel unavailable). Positive result confirms the diagnosis and specifies the subtype.

4

Cascade Testing

Offer predictive genetic testing to first-degree relatives. Identify asymptomatic carriers for early monitoring and appropriate management.

⚠️

Don't delay testing: Many patients with MODY 3 have spent years on unnecessary insulin therapy before correct diagnosis. If clinical features suggest MODY, refer for genetic testing promptly. A confirmed MODY 3 diagnosis may allow transition from insulin to sulphonylureas.

Differentiation from T1DM and T2DM

Distinguishing MODY from T1DM and T2DM is essential for appropriate management. The table below summarises key distinguishing features.

Feature	T1DM	T2DM	MODY
Age of onset	Any age; peaks in childhood/adolescence	Usually > 40 years (increasingly younger)	Typically < 25 years (some subtypes later)
BMI	Usually normal	Usually overweight/obese	Usually normal
Family history pattern	Polygenic; ~10 % have FHx	Polygenic; strong FHx common	Autosomal dominant; ≥ 2 generations affected
Autoantibodies (GAD, IA-2)	Positive (85–90 %)	Negative	Negative
C-peptide	Low/undetectable	Normal or elevated	Preserved (detectable, often normal)
DKA risk	High	Low (unless severe illness)	Very low (except MODY 5 with pancreatic atrophy)
Insulin resistance	Absent initially	Central feature	Absent
Metabolic syndrome	No	Common	No
HbA1c at diagnosis	Often markedly elevated (> 8.5 %)	Variable (6.5–10 %)	MODY 2: 5.8–7.6 %; MODY 3: variable, progressive
Treatment response	Insulin essential	Lifestyle + metformin ± other agents	MODY 2: usually none; MODY 3: sulphonylureas first-line

ℹ️

Practical tip: The Royal Devon & Exeter MODY Probability Calculator (available online) uses age at diagnosis, HbA1c, BMI, and parental diabetes status to estimate the probability of MODY. It is a useful screening tool in the Australian primary care setting.

Management — Sulphonylureas for MODY 2 & 3

Management of MODY depends on the subtype. Accurate genetic diagnosis directly informs pharmacotherapy.

MODY 2 (GCK) — Management

✅

MODY 2 patients usually require no treatment. The mild, stable fasting hyperglycaemia (5.5–8.0 mmol/L) does not progress significantly and microvascular complication risk is low. Pharmacotherapy is not recommended unless coexisting conditions (e.g., pregnancy, concomitant T2DM) demand tighter glycaemic control.

Monitoring: Annual HbA1c; fasting glucose self-monitoring not routinely required
During pregnancy: Insulin may be required if foetal growth is affected (foetal MODY 2 genotype determines foetal hyperglycaemia risk)
Patient education: Reassurance that the condition is benign; avoid unnecessary dietary restriction or medication

MODY 3 (HNF1A) — Management

MODY 3 patients are exquisitely sensitive to sulphonylureas — they require doses approximately 25–50 % of those used in T2DM. Sulphonylureas are first-line therapy and remain effective long-term.

💊

Gliclazide

Diamicron® · Generic · Sulphonylurea

Adult dose 20–40 mg PO once daily (start low); titrate to max 80 mg daily if needed

Paediatric dose 0.1–0.2 mg/kg PO once daily; start at 20 mg and adjust

Renal adjustment Use with caution if eGFR < 30 mL/min/1.73 m²; start at lowest dose

PBS status ✔ PBS General Benefit

💊

Glyburide (Glibenclamide)

Daonil® · Generic · Sulphonylurea

Adult dose 1.25–2.5 mg PO once daily (start low); max 5 mg daily

Paediatric dose 0.05–0.1 mg/kg PO once daily; preferred in neonatal diabetes / MODY 1

Renal adjustment Avoid if eGFR < 30 mL/min/1.73 m² (hypoglycaemia risk)

PBS status ✔ PBS General Benefit

MODY 1 (HNF4A) — Management

Similar to MODY 3, MODY 1 patients respond well to sulphonylureas. Therapy typically starts at low doses and is titrated to glycaemic targets. Insulin may be required in later life as beta-cell function declines.

MODY 5 (HNF1B) — Management

MODY 5 is frequently associated with pancreatic atrophy or hypoplasia, resulting in significant insulin deficiency. Most patients require insulin therapy from diagnosis. Sulphonylureas are generally ineffective due to inadequate beta-cell mass. Renal function monitoring is essential given the association with renal cystic disease.

⚠️

Critical safety point: MODY 3 patients transitioning from insulin to sulphonylureas require close supervision. Start sulphonylurea at a very low dose, monitor capillary blood glucose 4–6 times daily for the first 2 weeks, and taper insulin gradually over 1–2 weeks under specialist guidance. Risk of hypoglycaemia is significant during transition.

Glycaemic Targets

Parameter	Target	Notes
HbA1c	≤ 6.5 % (48 mmol/mol)	Individualise; MODY 2 patients typically < 7.0 % without treatment
Fasting glucose	4.0–7.0 mmol/L	MODY 2 patients may run 5.5–8.0 mmol/L — this is acceptable
Postprandial glucose	< 10.0 mmol/L	Particularly relevant for MODY 3 on sulphonylureas

Special Populations

🤰

Pregnancy

MODY 2:

Maternal fasting hyperglycaemia is usually benign. If foetal growth is excessive, consider insulin therapy. Foetal genotype determines whether the foetus has MODY 2 (and thus mild hyperglycaemia is expected) or is unaffected (and thus maternal hyperglycaemia poses risks).

MODY 3:

Sulphonylureas (glibenclamide) may be continued in early pregnancy but insulin is preferred in the second and third trimesters, consistent with RANZCOG guidelines. Genetic counselling regarding 50 % transmission risk is recommended.

👶

Paediatrics

Diagnosis:

Consider MODY in any non-obese child with diabetes who lacks autoantibodies and has detectable C-peptide. Neonatal diabetes (onset < 6 months) warrants urgent genetic testing.

MODY 3 treatment:

Gliclazide 0.1–0.2 mg/kg/day or glibenclamide 0.05–0.1 mg/kg/day. Monitor closely for hypoglycaemia. Avoid metformin as monotherapy in paediatric MODY.

👴

Elderly

Hypoglycaemia risk:

Sulphonylurea doses should be reduced in elderly patients with MODY 3. HbA1c targets may be relaxed to 7.0–7.5 % to reduce hypoglycaemia risk.

Renal function:

Declining eGFR increases sulphonylurea hypoglycaemia risk. Monitor renal function annually and adjust doses.

🫘

Renal Impairment

MODY 5:

Renal cystic disease is intrinsic to MODY 5; monitor eGFR and urine ACR. Insulin is preferred as sulphonylurea clearance is impaired.

MODY 3 with CKD:

Reduce gliclazide dose if eGFR < 30; avoid glibenclamide. Insulin may be safer. Consult nephrology.

🫁

Hepatic Impairment

Caution:

Sulphonylureas are hepatically metabolised. Use lowest possible doses in hepatic impairment. Gliclazide is preferred over glibenclamide due to shorter half-life. Monitor LFTs.

🛡️

Immunocompromised

No specific MODY-related concerns:

Standard diabetes management principles apply. During intercurrent illness, monitor blood glucose frequently; sulphonylureas may need temporary dose reduction if oral intake is poor.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology

Type 2 diabetes is 3–4 times more prevalent in Aboriginal and Torres Strait Islander peoples compared with non-Indigenous Australians (AIHW, 2023). MODY is likely underdiagnosed in this population due to the high background rate of T2DM; young non-obese Indigenous patients with familial diabetes should be considered for genetic testing.

Diagnostic access

Genetic testing services are concentrated in metropolitan centres. Aboriginal and Torres Strait Islander peoples in remote and very remote communities face significant barriers to specialist referral, genetics consultation, and sample collection. Telehealth-enabled genetic counselling and buccal swab collection via Aboriginal Health Workers can improve access.

Medication access

Gliclazide and glibenclamide are available as PBS General Benefits and through Closing the Gap PBS co-payment arrangements, reducing out-of-pocket costs for eligible Aboriginal and Torres Strait Islander patients. Ensuring prescriptions are correctly annotated with the CTG indicator is essential.

Cultural safety

Genetic counselling must be delivered in a culturally safe manner. Concepts of inheritance, autosomal dominant transmission, and predictive testing should be explained with the support of Aboriginal Health Workers or Liaison Officers where available. Kinship considerations may affect disclosure of genetic information within families.

Remote management

In remote communities, HbA1c testing (via portable analysers or postal samples) and point-of-care glucose monitoring are essential. Telehealth endocrinology consultations via the Australian Telehealth Network can support ongoing MODY management. Integration with Aboriginal Community Controlled Health Organisations (ACCHOs) improves continuity of care.

📚 References

1. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504–2508.
2. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60(5):769–777.
3. Naylor RN, Greeley SAW, Bell GI, Philipson LH. Genetics and pathophysiology of neonatal diabetes mellitus. J Clin Invest. 2011;121(12):4513–4521.
4. McDonald TJ, Ellard S. Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem. 2013;50(Pt 5):403–415.
5. Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467–477.
6. Bacon S, Kyithar MP, Rizvi SR, et al. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabet Med. 2016;33(7):976–984.
7. Australian Institute of Health and Welfare (AIHW). Diabetes: Australian Facts. Canberra: AIHW; 2023.
8. Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Management of Pre-existing Diabetes in Pregnancy (C-Obs 60). Melbourne: RANZCOG; 2021.
9. The Royal Australian College of General Practitioners (RACGP). General Practice Management of Type 2 Diabetes: 2016–2018. East Melbourne: RACGP; 2016.
10. National Health and Medical Research Council (NHMRC). National Evidence-Based Guideline: Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes. Canberra: NHMRC; 2015.
11. Johansson BB, Irgens HU, Molnes J, et al. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia. 2017;60(4):625–635.
12. Royal Devon and Exeter NHS Foundation Trust. MODY Probability Calculator. Available from: https://www.diabetesgenes.org/exeter-mody-probability-calculator.